{"title":"Research advances in single-molecule multi-target strategies targeting ferroptosis for colorectal cancer treatment.","authors":"Zirui Weng, Yingting Zhu, Weirong Yin, Jingyu Zhang, Luohang Ni, Xueting Deng, Lin Miao","doi":"10.62347/KLUJ3717","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a highly prevalent malignancy worldwide, with its incidence and mortality continuing to rise, and with an emerging trend toward younger-onset disease. The efficacy of current treatment modalities, including surgery, chemotherapy, targeted therapy, and immunotherapy, is often limited by the development of drug resistance. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is governed by a sophisticated regulatory network comprising core pathways and bypass systems in CRC, offering numerous potential targets for therapeutic intervention. The single-molecule multi-target strategy employs a single compound to simultaneously act upon multiple key nodes within this network, circumventing the resistance commonly associated with single-target agents while avoiding the pharmacokinetic interactions and additive toxicities of drug combinations. This review systematically delineates the key pathways and core targets of ferroptosis in CRC and summarizes recent progress across three classes of single-molecule multi-target compounds: natural products, synthetic small molecules, and \"one-drug multi-modal death\" inducers. We further propose a drug development and design framework integrating structural optimization, target integration, and delivery efficiency. Finally, we discuss current challenges and future directions, aiming to provide a theoretical foundation for developing novel CRC treatment strategies.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 8","pages":"3319-3337"},"PeriodicalIF":3.1000,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559282/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/KLUJ3717","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Colorectal cancer (CRC) is a highly prevalent malignancy worldwide, with its incidence and mortality continuing to rise, and with an emerging trend toward younger-onset disease. The efficacy of current treatment modalities, including surgery, chemotherapy, targeted therapy, and immunotherapy, is often limited by the development of drug resistance. Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, is governed by a sophisticated regulatory network comprising core pathways and bypass systems in CRC, offering numerous potential targets for therapeutic intervention. The single-molecule multi-target strategy employs a single compound to simultaneously act upon multiple key nodes within this network, circumventing the resistance commonly associated with single-target agents while avoiding the pharmacokinetic interactions and additive toxicities of drug combinations. This review systematically delineates the key pathways and core targets of ferroptosis in CRC and summarizes recent progress across three classes of single-molecule multi-target compounds: natural products, synthetic small molecules, and "one-drug multi-modal death" inducers. We further propose a drug development and design framework integrating structural optimization, target integration, and delivery efficiency. Finally, we discuss current challenges and future directions, aiming to provide a theoretical foundation for developing novel CRC treatment strategies.
期刊介绍:
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.